Leiden University Medical Center

The Leiden University Medical Center is advancing knowledge in blood‑related cancers, with a focus on high risk diffuse large B-cell lymphoma. Researchers are testing innovative treatment combinations to improve long‑term survival and reduce relapse rates.

• Atezolizumab consolidation therapy
• R-CHOP induction regimen
• 2‑year disease‑free survival evaluation

Three investigators are conducting three independent trials, all within a non‑commercial hospital environment, to generate robust data for future therapeutic guidelines.

In the field of high risk diffuse large B-cell lymphoma, the site evaluates patients who achieve complete metabolic remission after standard chemotherapy, aiming to determine the added benefit of checkpoint‑inhibitor consolidation.

• Metabolic remission as a surrogate endpoint
• Feasibility of immunotherapy after R-CHOP
• Long‑term outcome monitoring

Located in Leiden, Netherlands, the department leverages its expertise in hematology to generate evidence that may shape future treatment standards for this aggressive lymphoma.